LUME-Lung 3.

• Research type

  Research Study

• Full title

  A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.

• IRAS ID

  50763

• Contact name

  Siow Ming Lee

• Eudract number

  2010-019707-32

• ISRCTN Number

  Not Submitted

• Research summary

  Lung cancer is the most common cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 80% of all newly diagnosed cases. NSCLC presents with 2 types of histology: non-squamous and squamous. While there are positive developments in treating non-squamous NSCLC, squamous cell type is much harder to treat. Approximately 30% of NSCLC is of the squamous type and the current chemotherapy of choice internationally is a combination of cisplatin and gemcitabine. The 1199.82 study is designed to see if adding the investigational drug BIBF 1120, given orally twice a day, can improve clinical efficacy.If the results of the Phase II are positive, we will conduct a confirmatory Phase III trial

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  10/H0720/88

• Date of REC Opinion

  26 Nov 2010

• REC opinion

  Favourable Opinion